Universe Pharmaceuticals INC
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
About Universe Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
Universe Pharmaceuticals INC is a Cayman Islands holding company that operates through its subsidiaries in China, primarily Jiangxi Universe Pharmaceuticals Co., Ltd. and its operating entities. The company engages in the traditional Chinese medicine (TCM) and traditional Chinese medicine derivatives (TCMD) business sectors, with dedicated research and commercial trading arms such as Guangzhou Universe Hanhe Medical Research Co., Ltd. and Jiangxi Universe Pharmaceuticals Trade Co., Ltd.
The company's operations and operating entities are located entirely within the People's Republic of China, with principal executive offices situated in Ji'an, Jiangxi Province. As a holding vehicle, the entity maintains an international intermediate structure through Universe Pharmaceuticals Group (International) Limited in Hong Kong, which directly owns its PRC-based management entity, Jiangxi Universe Pharmaceuticals Technology Co., Ltd.
Summary of the business section of Universe Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Universe Pharmaceuticals INC
- Founded
- 2010
- Headquarters
- Ji'An, Jiangxi, F4
- Address
- 265 Jingjiu Avenue, Jinggangshan Econ. And Tech. Dev. Zone 343100
- Phone
- 86-0796-8403309
- Website
- universe-pharmacy.com
- Employees
- 225, Sep 30, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- F4
- Fiscal year ends
- September 30
- Auditor
- Enrome LLP, Singapore
Stock & identifiers
- Ticker
- UPC
- Exchange
- Nasdaq
- IPO date
- Mar 24, 2021
- Shares outstanding
- 1M, Sep 30, 2025
- Filer category
- Non-accelerated filer<br>Emerging growth company
- Stock splits
- 1-for-600 reverse, Apr 29, 2025; 1-for-40 reverse, Mar 24, 2025; 1-for-15 reverse, Nov 18, 2024; 1-for-6 reverse, Aug 31, 2023; 1-for-6 reverse, Jul 28, 2023
- SEC CIK
- 1809616
- CUSIP
- G9442G138
- ISIN
- USG9442G1381
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Gang Lai | Chief Executive Officer, Director | 87,967 |
| Lin (Lydia) Yang | Chief Financial Officer, Director | – |
| Baochang Liu | Chief Operating Officer | – |
| Jiawen Pang | Director | – |
| Yongping Yu | Director | – |
| Ding Zheng | Director | – |
Employees
Headcount reported in annual reports
“As of September 30, 2025, 2024 and 2023, we had a total of 216, 225 and 225 employees, all of whom are located in China.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jan 27, 2025 | Late filing | Notification of late filing |
| Jan 30, 2023 | Late filing | Notification of late filing |
| Mar 24, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Mar 17, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |